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Objective

Results
ALT with Equivocal Cytologic Atypia2

Determine the clinical significance of
testing for MDM2 gene amplification in
Lipomatous tumors of the extremities.

312 patients were identified: 205 lipomas and
107 ALTs. Overall recurrence was 3.9% of
patients (n=8) for lipomas and 27.1% of
patients (n=29) for ALTs.
Lipomas Vs ALTs Identified
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Lipomas of the extremities are benign
soft tumors of adipocytic origin.
Extremity Atypical Lipomatous Tumors or
Well-Differentiated Liposarcomas
(ALT/LS-WD) are low-grade tumors of
adipocytic origin but with a potential of
local recurrence1. Differentiating
between lipomas and ALT/LS-WD based
on imaging can be difficult.
Differentiation often relies on both
histological analysis and cytogenetic
studies. ALTs are characterized by
amplification of the MDM2 gene (12q1315) and thus cytogenetic MDM2 testing
can be a useful tool to establish a
diagnosis2. However, the question arises
whether ubiquitous testing of lipomas
and ALT’s is necessary and whether this
knowledge changes the treatment
algorithm for the patient.
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In total 50% of the 312-patient cohort (n=156)
were tested for MDM2: of 205 lipomas,
44.87% (n=92) and of the 107 ALTs, 59.8%
(n=64).
MDM2 Testing Among Lipomatous Tumors
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We evaluated patients diagnosed
with ALT/LS-WD and Lipoma
between 2011 and 2020.
Demographic data, tumor location,
treatment, and pathology were
reviewed.
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Methods

In terms of follow-up, patients from the
ALT group had a significantly longer
(p<.01) duration of follow-up, after
primary surgical excision, than the
patients in the lipoma group. The mean
duration of follow-up after primary
surgical excision for lipomas was 10.4
months, while mean duration of follow-up
for ALTs after primary surgical excision
was 29.6 months. There was no
significant difference between the followup duration after primary surgical
excision of lipomas tested for MDM2 and
lipomas not tested. In addition, there was
no significant difference in follow-up
duration after primary surgical excision
between ALTs tested for MDM2 and ALTs
not tested.
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Of the lipomas tested for MDM2, 15.22%
(n=14) tested positive, but only 4 of the
lipomas that tested positive for MDM2
recurred. Treatment for these 4 recurrent
lipomas was surgical excision. Of the 4
recurrent lipomas that were either negative
or not tested for MDM2, 2 were treated with
surgical excision, 1 was lost to follow-up,
and 1 was treated with observation.
Treatment of the vast majority of patients
who recurred, 91.89% (n=34), was surgical
excision.

8/205 lipomas recurred, and the mean
follow-up was 10.4 months. Time to
recurrences was between 24 and 96
months. Of the 8 patients in the lipoma
group who recurred, 4 were positive for
MDM2, but only 3 lipoma patients were
still in follow-up. Mean follow-up for the
ALTs was 29.6 months, and 29/107 ALT
patients recurred. The time to
recurrences was between 12 and 90
months. 20/29 were in current follow-up
but only 10 of these were tested and
positive for MDM2.

Lipoma2

Conclusion
Our results suggest that a more selective
approach to using MDM2 testing is
warranted. The majority of the Lipomas
tested for MDM2 were negative, and of
those that came back positive, only 4
resulted in recurrence. While there was a
difference in recurrence between lipomas
and ALTs, there was no difference in time
to recurrence. Treatment of recurrent
lipomas/ALTs was surgical excision,
whether or not the tumor was positive for
MDM2. MDM2 testing is not without
financial cost, and in this cohort, testing
provided little to no change to the
treatment options. Thus, we support the
recent recommendations in the literature
to limit testing for MDM2 to recurrent
lipomas, lipomatous tumors with equivocal
cytologic atypia, and deep extremity
tumors larger than 10cm in patients over
fifty2.
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